Advancing understanding of mature T-cell and natural killer-cell lymphomas
Cet article examine les limites des traitements conventionnels et des nouvelles approches thérapeutiques pour les lymphomes à lymphocytes T matures ou à cellules NK
Mature T-cell and natural killer-cell lymphomas are rare, aggressive, and heterogenous malignancies, accounting for approximately 10–15% of non-Hodgkin lymphomas globally. Their striking geographic, ethnic, and molecular variations reflect the interplay between genetic predispositions, environmental exposures, and oncogenic drivers. For decades, outcomes have lagged behind those of aggressive B-cell lymphomas. This Series about mature T-cell and natural killer-cell lymphomas, published in The Lancet Regional Health—Western Pacific and The Lancet Haematology, offers a comprehensive, integrated perspective. The Series bridges knowledge gaps, from population-level patterns to mechanistic insights and clinical innovations, providing a roadmap for precision medicine in this challenging field.
The Lancet Haematology , commentaire, 2025